Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 11, 2025Annals of HematologyOpen Access

Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: a real-world study

View Full Paper
Ask AI
Bookmark
Share

Authors

TYToshiki YamadaNNNobuhiko NakamuraHGHideko Goto

Discussion

Loading...

Member takes

Overview

Retrospective cohort study shows 89.5% overall response rate in patients aged ≥80 years, highlighting treatment-related mortality concerns.

Key Points

  • Overall response rate was 89.5% in patients aged ≥80, indicating promising efficacy in elderly patients.
  • Treatment-related mortality was notably higher at 11.4% in the older group compared to 2.3% in younger patients.
  • Cautious toxicity management is essential, with individualized dose modifications suggested to improve tolerability.
  • Higher dose intensity of polatuzumab vedotin was linked to more severe adverse events, emphasizing the need for nutritional assessments.

Cite This Study

Yamada et al. (2025) studied this question.

synapsesocial.com/papers/68ea72339f1bd4df558cedfahttps://doi.org/10.1007/s00277-025-06619-0
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R- CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: A real- world study2025
  2. 2Clinical Outcomes of Pola-R-CHP Therapy in Patients Aged >80 Years With Diffuse Large B-Cell Lymphoma2026
  3. 3Real‐World Safety and Efficacy of Pola‐R‐ <scp>CHP</scp> in Previously Untreated <scp>DLBCL</scp> : <scp>POLASTAR</scp> Interim Analysis of 500 Patients2026
  4. 4Phase 2 trial of polatuzumab vedotin, rituximab and dose attenuated CHP in patients 75 years and older with large B-cell lymphoma2025
  5. 5Clinical efficacy and safety of polatuzumab vedotin, rituximab, and zanubrutinib (POLA-Z-R) therapy in treatment of super-elderly patients with DLBCL: A real-world retrospective study2025